Department of Ophthalmology, Gaziantep University School of Medicine, Gaziantep, Turkey; and.
Department of Ophthalmology, Meram School of Medicine, Necmettin Erbakan University, Konya, Turkey.
Cornea. 2021 Aug 1;40(8):1007-1010. doi: 10.1097/ICO.0000000000002524.
To evaluate the outcomes of Descemet membrane endothelial keratoplasty (DMEK) in patients with toxic anterior segment syndrome (TASS).
Thirteen eyes of 13 patients who underwent DMEK for endothelial decompensation secondary to TASS were retrospectively reviewed. A comprehensive ocular examination including best-corrected visual acuity (BCVA), slitlamp biomicroscopy, intraocular pressure measurement, fundus evaluation, and measurement of central corneal thickness were performed in all patients at preoperatively and postoperatively.
There were 8 men and 5 women, with an average age of 56 ± 19 years. The mean follow-up was 8.7 ± 3.5 months. The time interval between the onset of TASS and DMEK was 4.9.±6.6 months (range, 1.5-26 months). Twelve of 13 grafts were clear at last visit. The mean preoperative BCVA was 20/666 (range, hand motion to 20/200), and the mean BCVA was 20/36 (range, hand motion to 20/20) at the postoperative last visit (P = 0.003). The decrease in mean pachymetry from preoperative (768 ± 69 μm) to postoperative last visit (523 ± 71 μm) was statistically significant (P < 0.001).
DMEK seems to be a safe and an effective treatment option in eyes with TASS-related endothelial decompensation.
评估治疗毒性前节综合征(TASS)相关的角膜内皮失代偿的 Descemet 膜内皮角膜移植术(DMEK)的效果。
回顾性分析了 13 例(13 只眼)因 TASS 导致的角膜内皮失代偿而行 DMEK 的患者。所有患者均进行了全面的眼部检查,包括最佳矫正视力(BCVA)、裂隙灯显微镜检查、眼压测量、眼底评估和中央角膜厚度测量。
男性 8 例,女性 5 例,平均年龄 56±19 岁。平均随访 8.7±3.5 个月。TASS 发病至 DMEK 的时间间隔为 4.9±6.6 个月(范围为 1.5-26 个月)。13 个移植物中有 12 个在最后一次随访时是透明的。术前 BCVA 平均为 20/666(范围为手动至 20/200),术后最后一次随访时平均 BCVA 为 20/36(范围为手动至 20/20)(P=0.003)。术前平均角膜厚度(768±69μm)和术后最后一次随访时(523±71μm)的平均角膜厚度均显著降低(P<0.001)。
DMEK 似乎是治疗 TASS 相关角膜内皮失代偿的一种安全有效的治疗选择。